GLONGHUI, January 23 | Recobiology (2179.HK) recently signed a framework agreement with Saudi Arabian pharmaceutical company SPIMACO on the recombinant nine-valent HPV vaccine REC603 and reached authorization and strategic cooperation. According to the agreement, Ricoh Biotech exclusively authorized SPIMACO to develop, register and commercialize the recombinant nine-valent HPV vaccine REC603 in 15 Middle Eastern and North African countries, including Saudi Arabia. The strategic cooperation covered the total population of about 380 million countries in the Middle East and North Africa. Cervical cancer is the eighth most common cancer in Saudi Arabia and the eighth most chronic cancer among women aged 15-44. The nine-valent HPV vaccine is widely regarded as the most effective vaccine against HPV. It can prevent about 90% of cervical cancer and 90% of anal and genital warts. SPIMACO is one of the largest listed pharmaceutical companies in Saudi Arabia. It is deeply involved in government tenders and private self-funded markets in the Middle East and North Africa region, and its products cover a wide range of Middle Eastern and North African countries. The cooperation between Recobiotics and SPIMACO will help open up markets in the Middle East and North Africa and accelerate the commercialization process of innovative vaccines.